Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts in the human genome which perform crucial functions in diverse biological processes. The abnormal expression of some lncRNAs has been found in tumorigenesis, development and therapy resistance of cancers. They may act as oncogenes or tumour suppressors and can be used as diagnostic or prognostic markers, prompting their therapeu- 
| INTRODUCTION
Cancer is a class of disease with the potential to proliferate continuously due to stepwise alterations at the genetic, epigenetic and cellular levels. It has become a great threat to human health. Though having been extensively studied, multidrug resistance (MDR) of tumour cells remains to be an obvious barrier of cancer treatments.
Therefore, a better understanding of mechanisms in tumorigenesis, progression and drug resistance in cancer will be imperative for the development of efficient therapeutic strategies. Recently, more and more reports revealed that mutations within the non-coding genome have a close relationship with tumour biology.
Results from the latest GENCODE have indicated that there are only approximately 2% of the human genome are protein-coding genes, whereas the vast majority of the human genome is made up of non-coding RNAs (ncRNAs). 2 In the past decades, lots of ncRNAs have been found, such as ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA) and microRNA (miRNA) as well as long non-coding RNA (lncRNA). Aberrations within the non-coding genome are major decisive factors contributed to human diseases. 3 Among these non-protein-coding transcripts, lncRNAs, defined as longer than 200 nucleotides with little or no protein-coding ability, have emerged as essential regulators in diverse biological processes. [4] [5] [6] They can interplay with DNA, RNA and proteins to regulate the target gene expression. They can also influence several signalling pathways including Wnt/b-catenin signalling pathway, which is a common pathway involved in embryogenesis, development and homoeostasis of tissues. Aberrant regulation of the pathway is associated with human diseases. 7, 8 The comprehensive interrelationship of lncRNAs and Wnt/bcatenin signalling pathway has appeared as a significant tumorigenic signalling network in various cancers. In this review, we summarized some lncRNAs which are associated with Wnt/b-catenin signalling pathway to describe their interactions and underlying mechanisms in cancer formation, development and response to treatments.
| CHARACTERISTICS OF LNCRNAS AND THEIR FUNCTIONS IN CANCER
LncRNAs represent a novel heterogeneous group of ncRNAs that usually exhibit cell-type-specific expression manner. 9 The genomic locations of lncRNAs can be classified into intragenic, bidirectional and intergenic on the basis of their relationship to adjacent proteincoding transcripts. 10 They are initially transcribed through pathways similar to that of protein-coding genes. And their transcription is mediated via RNA polymerase II. 11, 12 Evidences have already indicated that lncRNAs can regulate gene expression at the epigenetic, transcriptional and post-transcriptional levels. 13 For example, lncRNA CCAT2, which is up-regulated in colorectal cancer (CRC), can enhance tumour invasion and metastasis by regulating c-Myc transcription and activate the Wnt signalling pathway. 14 LncRNA CCAT1
can promote the progression of gastric carcinoma depending on the post-transcriptional activity of c-Myc. 15 Functionally, lncRNAs are not the "transcriptional junk" any more. They play an important role in normal cellular proliferation and differentiation. 16 They are predominantly localized in the nucleus or cytoplasm, and their function is location-specific. 17 In nucleus, lncRNAs are involved in chromatin remodelling, transcriptional regulation and RNA processing, while cytoplasmic lncRNAs can modulate mRNA stability, splicing or translation regulation, interact with special proteins and influence cellular signalling cascades. 18 Studies have shown that dysregulated expression of lncRNAs leads to diverse human diseases. [19] [20] [21] At present, masses of lncRNAs are known to be associated with the initiation and progression of cancer. proliferation. The dysregulation of b-catenin and APC has also been found in sporadic colon cancer and some other kinds of tumours.
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In addition, Wnt pathway could function as a significant anticancer target in cancer treatments.
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| THE INTERACTIONS BETWEEN LNCRNAS AND WN T/b -CATENIN SIGNALLING PATHWAY
The Wnt pathway has been recognized as a pivotal pathway participated in the regulation of cell proliferation, tumorigenesis and progression as well as chemoresistance in various cancers. [40] [41] [42] Dysregulation of the multifunctional protein b-catenin, which is a crucial signalling effector in the pathway, contributes to aberrant activation of Wnt pathway. 43 Accumulating evidence demonstrated that lncRNAs could regulate several signal pathways via interacting with specific proteins. 44, 45 More recently, numerous lncRNAs have been found to target key molecules associated with Wnt pathway and affect the accumulation of b-catenin. Then, modulating Wnt target genes expression and cancer cell functions. 46, 47 For example, lncRNA CCAT2 was found to promote breast tumour progression by influencing the activity of b-catenin, and thus, activating the Wnt pathway. 48 These findings suggest that they may have close relationships with each other in cancer. Here, we enumerated some Wnt pathway-related lncRNAs to explore their reciprocities in tumorigenesis and progression, drug resistance and radiosensitivity of cancers (Table 1) . Their probable regulatory network was depicted in a schematic diagram ( Figure 2 ). We also provided a perspective that a better understanding of the interactions between Wnt pathways and these lncRNAs may devise efficient strategies against tumour treatments.
| LncRNAs and Wnt/b-catenin pathway in tumorigenesis and tumour progression
As is known to all, the ability to propagate continuously is one of 
| LncRNAs and Wnt/b-catenin pathway in therapeutical resistance
Chemotherapy is one of the major treatment methods of tumours.
Nevertheless, chemoresistance remains an obvious obstacle against satisfactory treatment outcomes. 57 may have the ability to become a potential diagnostic biomarker and a promising therapeutic target for CRC. 79 Another typical clinical application example is lncRNA PCA3, which is highly expressed in prostate cancer, can be detected in urine samples of patients and has been demonstrated to have greater sensitivity and specificity for the early diagnosis of prostate cancer than the normally used prostate-specific antigen (PSA) blood test. 80 Considering the functions of lncRNAs in cancer, recently, emerging studies have indicated that biological therapies targeting these lncRNAs by the use of small interfering RNAs, ribozymes, antisense oligonucleotides, and by the small molecule inhibitors may be novel approaches to fight against cancer. 81, 82 For example, CCAL is an oncogenic lncRNA that promotes the tumorigenesis and progression of colorectal cancer (CRC) through activation of Wnt pathway. Overexpression of CCAL was related to poor survival and poor response to adjuvant chemotherapy. CCAL knockout inhibited CRC cell proliferation, migration and invasion and induced cell apoptosis in vitro and in vivo, which make it a potential therapeutic target for CRC. 46 The lncRNA UCA1 is highly up-regulated and may be a reliable biomarker in bladder cancer. RNA interference-mediated down-regulation of UCA1 inhibited proliferation, migration and invasion of the bladder cancer cell, suggesting it can be a novel therapeutic target. 83 Nevertheless, the clinical use of the therapy targeting these lncRNAs is still in its infancy, there are many obstructions need to be solved before the clinical popularization of the lncRNA-based treatments.
On 
| CONCLUSION S AND PE RSPECTIVE
LncRNAs are a class of non-protein-coding RNAs, which play important roles in diverse biological processes. promote an efficient therapeutic strategy into a reality by targeting lncRNAs and/or Wnt pathway in cancer.
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